Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Allows Expanded Enrollment in Clinical Study of Signature Biologics' Investigational ...

12 August 2026 · By · Wire by Fusion42

Published

12 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

The FDA has authorised expanded enrollment of up to 30 additional subjects in Signature Biologics' clinical study of its investigational umbilical cord-derived mesenchymal stem cell therapy for Duchenne muscular dystrophy, with recruitment resuming after activation of a new clinical site.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now prepare for a larger patient pool as the FDA opens the door to test Signature Biologics’ cell therapy more broadly in DMD. Set up outreach to clinical investigators to position yourself ahead of accelerated recruitment.

◆ Coverage

1 source · 12 Aug 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvalclinical-trialscell-therapyDuchenne-muscular-dystrophybiotech